Management of Borderline Ovarian Tumors – state of the art

Abstract

Borderline ovarian tumors (BOT) have invited controversy for decades. In the last couple of years research has showed a shift towards less aggressive treatment. This review summarizes the latest studies and therapeutic consequences thereof. Staging procedures are recommended in the setting of serous BOT, but controversial in the setting of mucinous BOT, where they may represent overtreatment. Surgical staging is limited to bilateral salpingo-oophorectomy, peritoneal cytology/biopsies and an omentecomy. Neither a hysterectomy nor lymphadenectomy should be undertaken. Conservative management should consist of a cystectomy or unilateral salpingo-oophrectomy in the setting of serous BOT and unilateral salpingo-oophrectomy in the case of mucinous BOT. Bilateral disease should be treated by bilateral cystectomy whenever possible. At present, there are no data to support the use of adjuvant treatment in any setting of BOT. To cite this article: Ines Vasconcelos. Management of borderline ovarian tumors -state of the art. Uterus Ovary 2015; 2: e885.